GTCR Acquires Zentiva from Advent
Analysis based on 6 articles · First reported Apr 09, 2026 · Last updated Apr 12, 2026
The acquisition of Zentiva by GTCR is expected to positively impact the pharmaceutical and healthcare sectors by increasing investment in generic and over-the-counter medicines, potentially leading to broader access to affordable drugs. This transaction highlights the continued interest of private equity firms like GTCR in the healthcare industry, signaling potential for further consolidation and growth in the generics market.
GTCR, a leading private equity firm, has completed its acquisition of Zentiva, a prominent European generics pharmaceutical company, from Advent International. This strategic move aims to support Zentiva's next phase of growth, focusing on new product development, portfolio expansion, and increased geographic reach. Zentiva, which serves over 100 million people across more than 40 countries with generic, branded specialty, and over-the-counter medicines, will continue to be led by CEO Steffen Saltofte and Executive Chairperson Kieran Murphy. GTCR's investment aligns with its long-standing focus on healthcare and the growing demand for cost-effective pharmaceutical solutions. The transaction involved several financial and legal advisors, including Barclays, BNP Paribas, Morgan Stanley, and Kirkland & Ellis for GTCR, and Goldman Sachs, EQT AB, and Freshfields for Advent International.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard